Rodrigo Rafael Flores‐Mariñelarena

Hospital Médica Sur

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jorge Alatorre-Alexander

Instituto Nacional de Enfermedades Respiratorias

Jerónimo Rafael Rodríguez‐Cid

Hospital Médica Sur

Luis Manuel Martínez-Barrera

Instituto Nacional de Enfermedades Respiratorias

Carla Paola Sánchez‐Ríos

Instituto Nacional de Enfermedades Respiratorias

Iván Romarico González-Espinoza

Clínica Ruiz

José Fabián Martínez‐Herrera

Centro Médico ABC

Vanessa García-Montes

Hospital Español

Valeria Michelle Fernández‐Garibay

Hospital Médica Sur

Patricio Javier Santillán‐Doherty

Instituto Nacional de Enfermedades Respiratorias

Claudia Rodríguez-Silva

Hospital Universitario Dr José Eleuterio Gonzalez

Cooperative Institutions

Instituto Nacional de Enfermedades Respiratorias

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Centro Médico ABC

Scottish Intercollegiate Guidelines Network

National Institute of Cardiovascular Diseases

Hospital General Dr. Manuel Gea Gonzalez

Institute for Social Security and Services for State Workers

Hospital de Clínicas

Instituto Nacional del Cáncer

Tecnológico de Monterrey

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma

Thoracic Cancer (2020)

Anahí Castañeda‐Zárraga Jerónimo Rafael Rodríguez‐Cid Rodrigo Rafael Flores‐Mariñelarena Héctor Trinidad‐Bibiano José Fabián Martínez‐Herrera

A relationship between the EGFR signaling pathway expression in skin and the use of targeted cancer therapies has been previously demonstrated. Consistent evidence to support the use of skin biopsies as a surrogate for therapeutic evaluation is needed. The purpose of this study was to establish the relationship between the expression of EGFR signaling pathway markers in skin samples from EGFR-mutated metastatic lung adenocarcinoma patients and their response to tyrosine kinase inhibitors.This was a prospective single blind analysis of 35 skin biopsies from 31 patients with confirmed advanced EGFR-mutated lung adenocarcinoma. Immunohistochemistry was performed: EGFR, p27, Ki67, STAT3 and MAPK, as well as H&E histopathological analysis, in order to determine their treatment response to tyrosine kinase inhibitors.EGFR, Ki67, STAT3, stratum corneum thickness (number of layers and millimeters) from skin samples had a statistical correlation with an adequate treatment response (P = 0.025, 0.015, 0.017, 0.041, 0.039 respectively). EGFR, p27 and number of layers of the stratum corneum were related to a better median progression-free survival (P = 0.025 and P = 0.030).The relationship between EGFR pathway inhibition in the skin and oncological outcomes obtained explains the parallel biological effects of tyrosine kinase inhibitors. We hope that our work incites future research to help validate and assess the use of these markers as potential prognostic and predictive factors.

EGFR Inhibitors

10.1111/1759-7714.13657

Cite

Citations (1)

A Comparative Study of Immunotherapy as Second-Line Treatment and beyond in Patients with Advanced Non-Small-Cell Lung Carcinoma

Lung Cancer Management (2021)

Jerónimo Rafael Rodríguez‐Cid Sonia Carrasco-Cara Chards Iván Romarico González-Espinoza Vanessa García-Montes Julio César Garibay-Díaz

Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.

10.2217/lmt-2020-0027

Cite

Citations (3)

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma

JCO Global Oncology (2020)

Jerónimo Rafael Rodríguez‐Cid Saul Campos‐Gómez Vanessa García-Montes Manuel Magallanes-Maciel Rodrigo Rafael Flores‐Mariñelarena

The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.This was a retrospective review among 21 medical centers of 150 patients with a confirmed diagnosis of lung adenocarcinoma, included in a compassionate use program of nintedanib from March 2014 to September 2015. The current study aimed to analyze the effectiveness of nintedanib in combination with docetaxel in the Mexican population, using progression-free survival rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. In addition, we examined the toxicity profile of our study population as a secondary end point.After exclusion criteria, only 99 patients met the criteria for enrollment in the current study. From the total study population, 53 patients (53.5%) were male and 46 (46.5%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the compassionate use program. A total of 48 patients (48.5%) had partial response; 26 (26.3%), stable disease; 4 (4%), complete response; and 16 (16.2%), progression; and 5 (5%) were nonevaluable. We found a median progression-free survival of 5 months (95% CI, 4.3 to 5.7 months). The most common grade 3 or 4 adverse reactions were fatigue (14%) and diarrhea (13%).Nintedanib, as part of a chemotherapy regimen, is an effective option with an acceptable toxicity profile for advanced lung adenocarcinoma after first-line treatment progression.

Nintedanib

Regimen

Tolerability

10.1200/jgo.19.00330

Cite

Citations (1)

Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma

Journal of Thoracic Disease (2019)

Jerónimo Rafael Rodríguez‐Cid Orlando García-Acevedo Javier Benjamin-Contreras D. Bonilla-Molina Rodrigo Rafael Flores‐Mariñelarena

Background: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective estrogen receptor beta (ERβ) agonists increases the susceptibility to antitumor treatment. Methods: This was a retrospective single center study that analyzed the response of malignant pleural mesothelioma with an expression of ERβ to first-line chemotherapy. The study included patients with pleural mesothelioma pathologically confirmed between 2013 and 2016 at the National Institute for Respiratory Disease (INER), who underwent an immunohistochemistry assay for ERβ (mouse monoclonal antibody PPG5/10). The primary endpoint was the response to chemotherapy based on RECIST 1.1 according to the ERβ expression; secondary outcomes were the overall survival (OS) and progression-free survival (PFS). Results: We included 22 patients, regarding the expression of ERβ, 17 (77.2%) patients had high or moderate degree, while 5 (22.7%) had low degree or null expression. The response to treatment as by RECIST 1.1, 12 (54.5%) had partial response, 5 (22.7%) had stable disease, and 3 (13.6%) had progression. None of the patients had a complete response. Of those who had a partial response, 9 (75%) had a high or moderate degree of ERβ expression in tumor cells, and 3 (25%) had a low or null degree of expression. Conclusions: High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.

Estrogen receptor beta

Estrogen receptor alpha

BETA (programming language)

10.21037/jtd.2019.03.38

Cite

Citations (8)